A synthetic composite material as a bone graft and method thereof

Porous scaffolds were prepared by combining bioinert polymers such as polylactic acid and metal fluorophosphate glass powder, which solved the problems of slow biotransformation speed and insufficient load-bearing function of existing bone graft materials, and achieved biological activity and bioinduction , reduces costs and disease transmission risks and provides efficient bone transplant solutions.

CN115996767BActive Publication Date: 2024-11-01BONE SUBSTITUTES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180017355.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-02-26
Filing Date
2021-02-25
Publication Date
2024-11-01
Estimated Expiration
2041-02-25

AI Technical Summary

Technical Problem

The existing bone graft materials have shortcomings in terms of slow biotransformation speed, insufficient load-bearing function, high cost and risk of disease transmission, which is difficult to meet the clinical needs of bone lesions and tumor rescue operations.

Method used

Using a composite material composed of polylactic acid, polyD,L-lactic acid, polypropylene fumarate, propylene glycol and metal fluorophosphate glass powder, a homogeneous mixture is formed by magnetic stirring or ultrasonic treatment, and boiled through a hot glass plate. Evaporate solvent or direct ink printing technology to prepare porous scaffolds to achieve biological activity and biodegradability.

Benefits of technology

Biocompatibility, bioactivity, bioconductivity and bioinducibility are achieved, biotransformation time is shortened, patient incidence is reduced, surgical cost is reduced, and customized bone graft materials are provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GHA0000007284350000112
    Figure GHA0000007284350000112
  • Figure GHA0000007284350000122
    Figure GHA0000007284350000122
  • Figure GHA0000007284350000123
    Figure GHA0000007284350000123
Patent Text Reader

Abstract

The present invention provides a synthetic composite material for bone grafts, comprising: a bioinert polymer including polylactic acid, poly-D,L-lactic acid; a bioactive polymer consisting of polypropylene fumarate or fumaric acid diester and propylene glycol (1,2-diol); and a bioactive inorganic component consisting of metal fluorophosphate glass powder, wherein the amount of the bioactive component is up to 30% (w / w) of the composite material. The bioactive inorganic metal fluorophosphate glass powder in the composite material is one of zinc fluorophosphate, magnesium fluorophosphate or silver fluorophosphate. The present invention relates to a method for making a bracket, and also to a 3D printed bracket.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of composite materials. In particular, the present invention relates to a composite material of a biodegradable polymer and a bioactive fluorophosphate glass in the form of a powder or a scaffold as a synthetic bone graft, and a method for making the composite material. Background of the Invention

[0003] The number and type of grafts required by the clinician depends on the clinical situation and circumstances. A surgeon clearing a bone cyst will need a large amount of graft to fill the void, and to do so may require granular fillers to fill all the nooks and crannies. When the surgeon is faced with a case of nonunion of a long bone fracture, in order to introduce bridging callus, in addition to good fixation of the fracture, he will also need to trim the ends of the fracture to bring out and expose the mesenchymal cells to the outside, and lay an iliac bone graft (phemister graft) strip on it to induce and guide bone healing across the fracture site.

[0004] When a compound fracture with bone loss is encountered, and the cortical lesion requires the removal of a section of long bone, reconstruction requires a load-bearing bone graft that will replace the lost bone and convert biologically to bone in a short period of time without prolonging the patient's morbidity.

[0005] When the metaphysis of a bone is diseased and needs to be removed, limb salvage surgery is performed with a custom-made prosthesis without amputation. Since the prosthesis has a specific lifespan and can be used for fatigue fractures, the custom-made transplant implants made through rapid prototyping will transform into bone after implantation, which is a boon to patients compared to existing methods.

[0006] The need for synthetic bone is increasing with the increasing incidence of high-speed accidents, salvage surgery for bone lesions and tumors is increasing, and the surgeon's hand is limited by the availability of autografts due to their limited resources and the morbidity associated with fixation of a graft from another incision made from another site. Allografts or bone banks always carry the risk of disease transmission.

[0007] The materials used initially were ceramic hydroxyapatite and tricalcium phosphate as bone graft substitutes. Hydroxyapatite is only osteoconductive and rarely converts to bone even after many years. It cannot be used to replace load-bearing functions. Tricalcium phosphate has minimal osteoinductive capacity and osteoconductive ability, but no bioconversion ability.

[0008] To have the advantage of biotransformation, certain specific bone hormones like “bone morphogenetic principles” (abbreviated as BMP) came into use. Also like “demineralized bone matrix (DMB)” were marketed as bone graft substitutes. The basic problem with their use was the huge cost involved, they had good osteoinductivity but were not good bone conductors. HENCH introduced 45S5 glass, which was a breakthrough because it was made of cheap chemicals, was osteoconductive and osteoinductive, able to fuse with natural bone and was commercially available. The disadvantages of 45S5 glasses were that they had a very slow resorption rate, took longer to biotransform, and they could not be used as load-bearing implants. To circumvent these problems, silica-free phosphate bioglasses and metal oxide-doped bioglasses entered the field.

[0009] Standardization of the ideal molar percentage of fluoride allowed the invention of fluorophosphate glasses, which are much more bioactive than phosphate and silica glasses and have a higher bioconversion rate. Doping fluorophosphate glasses with metal oxides can improve their physical properties and bring the elastic modulus close to that of human bone. Building blocks of fluorophosphate glasses are essential for the molecules to be used for clinical purposes.

[0010] Therefore, there is a need in the art for a synthetic composite material that is biocompatible and possesses several other properties, such as bioactivity, biodegradability; non-toxic to the recipient; bioconductive; capable of biotransformation and processable into desired shapes as well as cost-effective.

[0011] Purpose of the Invention

[0012] The purpose of the present invention is to synthesize a composite material of a bio-inert polymer, a bio-active polymer and a bio-active inorganic component, wherein the bio-inert polymer comprises polylactic acid and poly-D,L-lactic acid, the bio-active polymer comprises polypropylene fumarate, fumaric acid diester and propylene glycol (1,2-diol), and the bio-active inorganic component comprises metal fluorophosphate glass powder.

[0013] Another object of the invention is a composite material for particles, scaffolds such as strips, cylinders and any other shape and a method for its manufacture.

[0014] Another object of the present invention is to be used for preparing a scaffold by 3D printing.

[0015] Summary of the Invention

[0016] The present invention provides a synthetic composite material for bone grafts, comprising: a bioinert polymer, which includes polylactic acid, poly D, L-lactic acid; a bioactive polymer, which is composed of polypropylene fumarate or fumaric acid diester and propylene glycol (1,2-diol); and a bioactive inorganic component, which is composed of metal fluorophosphate glass powder, wherein the amount of the bioactive component is up to 30% (w / w) of the composite material.

[0017] In one aspect of the present invention, the bioactive inorganic metal fluorophosphate glass powder of the composite material is one of zinc fluorophosphate, magnesium fluorophosphate or silver fluorophosphate.

[0018] In one aspect, the polylactic acid in the composite material is in the range of 54% (w / w) to 68% (w / w); the poly D,L-lactic acid is in the range of 10% (w / w) to 28% (w / w); the 1,2-diol is in the range of 3% (w / w) to 10% (w / w); the polypropylene fumarate is in the range of 3% (w / w) to 10% (w / w); and the fluorophosphate inorganic metal salt glass powder in the composite material is in the range of 10% (w / w) to 30% (w / w).

[0019] In some embodiments, the composite material is in the form of a powder or a scaffold. The scaffold is in the form of a strip, a cylinder, a tube, etc. during manufacture.

[0020] In one embodiment of the synthetic composite material of the present invention, it is prepared by a preparation method comprising the following steps: mixing the composite material in a solvent with a magnetic stirrer or ultrasonically treating it to obtain a uniform mixture; pouring the mixture on a hot glass plate to boil the solution; and evaporating the solvent by continuous boiling; obtaining a porous scaffold in which the components of the composite material are uniformly distributed and interconnected.

[0021] The porosity of the scaffold ranges from 20% to 40%.

[0022] Furthermore, the scaffold was also fabricated with a desired shape and desired porosity by a custom 3D printer via direct ink printing technology.

[0023] The method of obtaining the scaffold by a custom 3D printer via direct ink printing technology includes the following steps: The components of the composite material are homogenized and cooled to 10-30°C. The chamber temperature is maintained at 30-40°C. The ink is loaded into a pressure-controlled non-adhesive extruder. The input writing details are transmitted to the printer via a microchip. The nozzle diameter is fixed to 300 μm for easy extrusion. The volume flow rate is set to 5 mm. 3 / s. The spacing between the writing lines is 200 microns, and the number of layers is designed to be 10. The desired shape, thickness, porosity, and layer fed into the computer are written on the hot plate (100°C). The movement of the hot plate in the x, y, and z directions is also pre-set, and the commands are transmitted by the microchip. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 is a bar graph depicting the ALP activity of the dissolution products of metal oxide-doped FP glasses at various glass concentrations.

[0025] Figure 2a and 2b : Thermal study of FP and MgFP glass powders.

[0026] Figure 2c and 2d : Thermal study of ZnFP and TiFP glass powders.

[0027] Figure 2e and 2f : Thermal study of ZrFP and AgFP glass powders.

[0028] Figure 2g : Thermal study of SrFP glass powder.

[0029] Figure 3 represents the FTIR spectrum of PPF.

[0030] Figure 4 represents the DSC study of PPF, Figure 4a Indicates the glass transition temperature of PPF.

[0031] Figure 5 : FTIR spectrum of 1,2-propylene fumarate.

[0032] Figure 6 : TG study of 1,2-propylene glycol fumarate.

[0033] Figure 7 : Characterization and thermal analysis of PLA.

[0034] Figure 8 : Characterization and thermal analysis of PDLLA.

[0035] Fig. 9 : Fluorophosphate glass was prepared by quenching from 1200°C to instantaneous -170°C.

[0036] Fig.10 : Try to build a scaffold by changing the concentration of the polymer.

[0037] Fig.11 : Attempts to construct scaffolds were made by varying the concentration of FP salts.

[0038] Fig.12 : Cell adhesion studies on scaffolds associated with compositional changes.

[0039] Fig.13 : Cell adhesion studies on composite materials with respect to variations in composition and the presence or absence of porosity.

[0040] Fig.14 : Different scaffolds achieved by different scaffold construction methods.

[0041] Fig.14a : SEM images of scaffolds fabricated by gel compression.

[0042] Fig.14b : Scaffolds were prepared by gel foam casting under rapid heating.

[0043] Fig.15 : Cytotoxicity (MTT) assay of endothelial cells in the stent.

[0044] Fig.15a : Cytotoxicity (MTT) assay of endothelial cells in the stent (microscope photos).

[0045] Fig.16 : RT-PCR collagen II expression of AgFP and ZnFP based scaffolds.

[0046] Fig.17 : RT-PCR osteocalcin expression of AgFP- and ZnFP-based scaffolds.

[0047] Fig.18 : RT-PCR collagen II and osteocalcin expression of Mg-based scaffolds.

[0048] Fig.19 : RT_PCR RUN_X2 expression of scaffolds.

[0049] Fig. 20 : Chondroitin sulfate levels expressed by scaffolds in SaOS2 cell line.

[0050] Fig.21 : FTIR spectra of PPF based scaffolds (in vitro evaluation - before and after immersion).

[0051] Fig.21a : Interpretation of PPF-based scaffolds (in vitro evaluation - before and after immersion).

[0052] Fig. 22 : FTIR spectra of diol-based scaffolds (in vitro evaluation - before and after immersion).

[0053] Fig.22a: Interpretation of diol-based scaffolds (in vitro evaluation - before and after immersion).

[0054] Fig.23 : FTIR spectra of MgFP based scaffolds (in vitro evaluation - before and after immersion).

[0055] Fig.23a : Interpretation of MgFP-based scaffolds (in vitro evaluation - before and after immersion).

[0056] Fig.24 : FTIR spectra of AgFP, ZnFP, MgFP scaffolds (scaffolds constructed by gel foam under rapid heating) (in vitro evaluation - before and after immersion).

[0057] Fig.24a : Explanation of AgFP, ZnFP, MgFP scaffolds constructed by gel foam casting under rapid heating (in vitro evaluation - before and after immersion).

[0058] Fig.25 : FTIR spectra of the strip scaffolds (in vitro evaluation - before and after immersion).

[0059] Fig.25a : Interpretation of strip scaffolds (in vitro evaluation - before and after immersion).

[0060] Fig.26 : FTIR spectra of cylindrical scaffolds (in vitro evaluation - before and after immersion).

[0061] Fig.26a : Interpretation of cylindrical scaffolds (in vitro evaluation - before and after immersion).

[0062] Fig. 27 : Photographs of ribbon and cylindrical scaffolds fabricated by gel foam casting under rapid heating.

[0063] Fig.28 : SEM micrographs before and after immersion in the support, at two different magnifications.

[0064] Fig.28a : Crystallization depth (from upper and lower surfaces) - intra-stent region assessed by SEM.

[0065] Fig.29 : Micro-CT evaluation of cylindrical samples before in vitro testing.

[0066] Fig.29a : Micro-CT evaluation of cylindrical samples after in vitro treatment.

[0067] Fig.30 : SEM image of the cylindrical scaffold (before immersion).

[0068] Fig.30a : SEM image of the cylindrical scaffold (after immersion).

[0069] Fig.30b : EDAX of samples before and after in vitro evaluation.

[0070] Fig.31 : SEM images of the tape-shaped scaffold (before and after immersion).

[0071] Fig.32 : Animal studies evaluating the efficacy of scaffold particles.

[0072] Fig.33 : Postoperative X-ray of the femur.

[0073] Fig.34 : X-ray examination of anatomical specimens.

[0074] Fig.35 : Sample snippets from research in HPE.

[0075] Figure 36: Histopathological evaluation of samples (EH staining and von Kossa staining).

[0076] Figure 37-abcd: Improved tetrachrome staining of the specimen.

[0077] Fig.38 : Animal studies evaluating the efficacy of ribbon composites.

[0078] Figures 39, 39a, 39b: X-ray examinations of three animals (A, B, C are AgFP, ZnFP, MgFP respectively) on day 0, day 1, day 9, and day 15.

[0079] Fig. 40, 40a, 40b: Day 19 CT scans of all three animals (AgFP, ZnFP, MgFP, respectively).

[0080] Fig.41 : Photographs of dissected samples (AgFP, ZnFP, MgFP, respectively).

[0081] Figure 42: X-ray of dissected samples (AgFP, ZnFP, MgFP respectively).

[0082] Fig.43a ,b,c,d: Histopathological evaluation of the samples (EH and Masson’s trichrome staining).

[0083] Fig.44a ,b,c,d: Histopathological evaluation of the specimens was performed by modified tetrachrome staining.

[0084] Figure 45(a): Control panel of the designed 3D printer.

[0085] Figure 45(b): Pressure-controlled, temperature-controlled extruder and temperature control console panel.

[0086] Figure 45(c): The printer during the printing process and the printed sample.

[0087] Table Legend

[0088] Table 1: Extracellular osteocalcin secretion produced by ionic lysates of various metal oxide-doped FP glasses in MG63 cells.

[0089] Table 2: Intracellular osteocalcin secretion produced by ionic lysates of various metal oxide-doped FP glasses in MG63 cells.

[0090] Table 3: Preparation of scaffolds by varying the ratio of FP glass.

[0091] Table 4: Effect of cell adhesion on scaffolds in MG63 cell line (as shown in Table 4).

[0092] Table 5: Scaffolds prepared by increasing the percentage of the bioactive components PPF and FP glass while decreasing the bioinert components PLA and PDLLA.

[0093] Table 6: Effect of cell adhesion on scaffolds in MG63 cell line (as shown in Table 5).

[0094] Table 7: Scaffolds prepared by varying the percentage of bioinert components PLA and PDLLA and keeping the bioactive components fixed (PPF and glass powder).

[0095] Table 7a: Scaffolds prepared by varying the percentage of bioinert components PLA and PDLLA and keeping the bioactive components fixed (1,2-diol and glass powder).

[0096] Table 8: Effect of cell adhesion on scaffolds in MG63 cell line (as shown in Table 7).

[0097] Table 8a: Effect of cell adhesion on scaffolds in MG63 cell line (as shown in Table 7a).

[0098] Table 9: MTT variation of SaOS2 cell line depending on the composition and the presence of pores.

[0099] Tables 10a and 10b: Composite materials and proportions of components in the composite materials.

[0100] Table 11: MTT of 12 types of scaffolds (different components, + / -PPF / XPPF, + / -pores) in SaOS2 cell line.

[0101] Table 12: ALP activity of composite materials.

[0102] Table 13: Chondroitin levels of scaffolds.

[0103] Table 14: Comparison of the bioactivity of scaffolds.

[0104] Table 15: In vitro studies - pH changes of scaffold simulated body fluid (SBF) over 21 days.

[0105] Table 16: XRD results of compression molded scaffolds after SBF impregnation.

[0106] Table 17: XRD results of the rapidly heated scaffolds after SBF impregnation.

[0107] Table 18: Percentage of scaffold crystallization in in vitro studies. DETAILED DESCRIPTION

[0108] The present invention provides a synthetic composite material for bone grafts, comprising: a bioinert polymer, which includes polylactic acid, poly D, L-lactic acid; a bioactive polymer, which is composed of polypropylene fumarate or fumaric acid diester and propylene glycol (1,2-diol); and a bioactive inorganic component, which is composed of metal fluorophosphate glass powder, wherein the amount of the bioactive component is up to 30% (w / w) of the composite material.

[0109] The bioactive inorganic metal fluorophosphate glass powder in the composite material is one of zinc fluorophosphate, magnesium fluorophosphate or silver fluorophosphate.

[0110] The polylactic acid in the composite material is in the range of 54% (w / w) to 68% (w / w); the poly D,L-lactic acid is in the range of 10% (w / w) to 28% (w / w); the 1,2-diol is in the range of 3% (w / w) to 10% (w / w); the polypropylene fumarate is in the range of 3% (w / w) to 10% (w / w); and the fluorophosphate inorganic metal salt glass powder in the composite material is in the range of 10% (w / w) to 30% (w / w).

[0111] In one aspect, the composite material includes polylactic acid, 1,2-diol, and zinc fluorophosphate.

[0112] In one aspect, the composite material includes polylactic acid, poly D,L-lactic acid, 1,2-diol and zinc fluorophosphate.

[0113] In one aspect, the composite material includes polylactic acid, polypropylene fumarate, and zinc fluorophosphate.

[0114] In one aspect, the composite material includes polylactic acid, poly D,L-lactic acid, polypropylene fumarate and zinc fluorophosphate.

[0115] In one aspect, the composite material includes polylactic acid, 1,2-diol, and magnesium fluorophosphate.

[0116] In one aspect, the composite material includes polylactic acid, poly D,L-lactic acid, 1,2-diol and magnesium fluorophosphate.

[0117] In one aspect, the composite material includes polylactic acid, polypropylene fumarate, and magnesium fluorophosphate.

[0118] In one aspect, the composite material includes polylactic acid, poly D,L-lactic acid, polypropylene fumarate and magnesium fluorophosphate.

[0119] In one aspect, the composite material includes polylactic acid, 1,2-diol, and silver fluorophosphate.

[0120] In one aspect, the composite material includes polylactic acid, poly D,L-lactic acid, 1,2-diol, and silver fluorophosphate.

[0121] In one aspect, the composite material includes polylactic acid, polypropylene fumarate, and silver fluorophosphate.

[0122] In one aspect, the composite material includes polylactic acid, poly D,L-lactic acid, polypropylene fumarate and silver fluorophosphate.

[0123] The composite material is in the form of powder or stent. The stent is in the form of a strip, a cylinder, a tube, etc. during manufacture.

[0124] The synthetic composite material of the present invention is prepared by a method comprising the following steps: mixing the composite material in a solvent with a magnetic stirrer or ultrasonic treatment to obtain a uniform mixture; pouring the mixture on a hot glass plate to boil the solution; and evaporating the solvent by continuous boiling to obtain a porous scaffold with uniformly distributed components of the composite material.

[0125] In one aspect, the solvent used in the method is one of dichloromethane, acetone or toluene or chloroform.

[0126] The porosity of the scaffold ranges from 20% to 40%.

[0127] Furthermore, the scaffolds were also fabricated with the desired shape and desired porosity by a custom 3D printer using direct ink printing technology.

[0128] The method of obtaining the scaffold by a custom 3D printer via direct ink printing technology includes the following steps: The components of the composite material are homogenized and cooled to 10-30°C. The chamber temperature is maintained at 30-40°C. The ink is loaded into a pressure-controlled non-adhesive extruder. The input writing details are transmitted to the printer via a microchip. The nozzle diameter is fixed to 300 μm for easy extrusion. The volume flow rate is set to 5 mm. 3 / s. The spacing between the writing lines is 200 microns, and the number of layers is designed to be 10. The desired shape, thickness, porosity, and layer fed into the computer are written on the hot plate (100°C). The movement of the hot plate in the x, y, and z directions is also pre-set, and the commands are transmitted by the microchip.

[0129] In one aspect, the biological evaluation of fluorophosphate glass is determined by its MTT, its intracellular and extracellular osteocalcin secretion, and ALP secretion associated with the MG63 cell line.

[0130] In one aspect, the importance of porosity in the scaffolds was evaluated by Calcein AM studies and MTT assessments.

[0131] In one embodiment, the biological potential of different composites with different component compositions has been determined by their efficiency in enhancing the secretion of alkaline phosphatase, chondroitin sulfate matrix in bone relative to MTT of SaOS2 and human endothelial cell lines.

[0132] In addition, RT-PCR was used to evaluate the ability of the composites in the secretion of osteocalcin, collagen ll, and RUN_X2. MicroCT evaluation was used to evaluate the porosity of the multilayered scaffolds.

[0133] In one embodiment, in vitro studies were done by immersing various composites and various scaffolds in SBF for 21 days and then studying by XRD, FTIR, SEM, and MicroCT.

[0134] In one embodiment, the bone formation efficacy of the composite material is evaluated by in vivo assessment in rabbits and confirmed by histopathological assessment.

[0135] In one aspect, the synthetic composite material has the following characteristics:

[0136] a) Biocompatibility; b) Bioactivity; c) Biodegradability; d) Non-toxic to the recipient; e) Bioconductivity; f) Bioinducibility; g) Bioconvertibility; h) Degradation rate matching the bioconversion rate; i) Sterilizability; j) Ease of mass production; k) Processability into desired shapes; l) Cost effectiveness.

[0137] Example:

[0138] The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention in any way.

[0139] Material:

[0140] Polylactic acid (PLA) and poly DL-lactic acid (PDLLA) were purchased from Japan Polypropylene fumarate (PPF) and fumaric acid diester and propylene glycol (1,2-diol) were purchased from Department of Polymer Technology, Kamaraj College of Engineering and Technology, SPGC Nagar, K. Velakulam-625701, India.

[0141] These polymers were synthesized at the Department of Polymer Technology, Kamaraj Institute of Engineering and Technology. The process involves adding diethyl fumarate, 1,2-propylene glycol, zinc chloride (catalyst) and hydroquinone (cross-linking inhibitor) in the ratio of 1.0:3.0:0.01:0.002 in a reaction vessel. The reaction vessel was equipped with a double-walled condenser to which a receiving flask was connected for by-product collection. The system was maintained in an oil bath at 100°C with effective magnetic stirring followed by application of vacuum (-80 mmHg). The temperature was raised to 150°C with continuous stirring and esterification condensation reaction took place. Thus, an intermediate bis(hydroxypropyl)fumaric acid diester was formed and ethanol was distilled out as the major by-product. After collecting the expected amount of ethanol, transesterification reaction was carried out to remove the excess 1,2-propylene glycol as the second by-product. The synthesized material was now dissolved in acetone. The solution was repeatedly washed with ice-cold distilled water to remove the unreacted reactants and catalyst. A sufficient amount of anhydrous sodium sulfate was added to the acetone solution of the polyester to dry the acetone solution. After filtration, the solvent was slowly evaporated in a hot air oven at 50°C to obtain PPF.

[0142] Fumaric acid (1.0 mol) and 1,2-propylene glycol (2.2 mol) were charged into a round bottom flask, and p-toluenesulfonic acid was used as an esterification catalyst. Dry toluene was added to the reaction mixture to remove water formed as an azeotrope during the esterification process. A Dean Stark apparatus was used for the above purpose. The reaction vessel was immersed in an oil bath and mixed evenly and continuously using a magnetic stirrer. The temperature was initially set to 100°C and gradually increased to 140°C in increments of 10°C over one hour. When the temperature reached 110°C (the boiling point of toluene), water began to be collected in the Dean Stark apparatus. The reaction was allowed to continue until a specified amount of water was collected. The material was purified by applying a vacuum to remove excess unreacted 1,2-propylene glycol and water.

[0143] The FP glass components of the present invention were purchased from Bone Substitutes, Madurai. The preparation method is described in Indian patent applications 5760 / CHE / 2013, 5990 / CHE / 2013, 5989 / CHE / 2013, and cited herein as references for the preparation of FP glass. The method is briefly summarized as follows. Take measured amounts of the required chemicals (Na2CO3, CaCO3, CaF2, P2O5 and ZnO / Ag2O / MgO), put them in a ball mill and homogenize them. Heat the mixture in an alumina crucible to 120°C for 1 hour and cool to room temperature. Ball mill again for 1 hour. Place the components in a platinum crucible and keep them in a furnace preheated to 1100°C for 90 minutes. Then sink the crucible into a bowl filled with liquid nitrogen. The formed glass is broken and ground for 48 hours to obtain nanopowders of specific fluorophosphate glass. The FP glass material was prepared at Bone Substitutes, Madurai, India.

[0144] MG-63( CRL-1427 TM ) was purchased from National Centre for Cell Science (NCCS), Pune, India.

[0145] Saos-2( HTB-85 TM ) was purchased from National Centre for Cell Science (NCCS), Pune, India.

[0146] Example 1: Selecting non-toxic inorganic fluorophosphate metal salt glass powder

[0147] a) MTT proliferation assay

[0148] MG-63 cells were cultured in 24-well plates, and ionic lysates of metal-doped bioglass (fluorophosphate (FP), magnesium fluorophosphate (MgFP), zinc fluorophosphate (ZnFP), titanium fluorophosphate (TiFP), zirconium fluorophosphate (ZrFP), silver fluorophosphate (AgFP), and strontium fluorophosphate (SrFP)) were co-treated with cells at 0 h of inoculation and monitored up to 48 h to study cell morphology, and then the cells were washed twice with 1XPBS and then incubated with 0.2 mg / mL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for 2 h. The purple product formed was then dissolved with isopropanol and the optical density (OD) was measured at 570 nm using an ELISA reader (Robonik, India). Figure 1 ). Figure 1 All metal oxide-doped fluorophosphate glasses were shown to be non-toxic and to have viabilities exceeding 80% (up to 10 μg / mL) after 48 h of incubation.

[0149] Alkaline phosphatase (ALP) is an essential enzyme in the process of bone formation from mesenchymal cells to the mineralization front. Therefore, enhancing its secretion is considered an important factor in selecting components for bone tissue engineering (BTE) composites. The results of the study on ALP secretion showed that AgFP, ZrFP, and MgFP showed consistently elevated levels at all concentrations of 0.1-100 μg / mL. ZnFP showed increased secretion only at lower concentrations of 0.01 and 1 μg / mL ( Figure 1 ).

[0150] b) Thermal assessment:

[0151] The thermal stability of the bioglass was determined using simultaneous thermal analysis (STA 449F3Nevio). 3.5 mg of each metal fluorophosphate was heated at 50 K min in a nitrogen atmosphere. -1 Heated to 1000°C. Figure 2a-2g ).

[0152] Thermal evaluation of all seven FP glasses showed that their Tg (glass transition temperature) was between 500-550°C and Tc (crystallization temperature) was around 700°C, indicating a large window width of about 150°C, which can be used for sintering when building the scaffold ( Figure 2a-2g ).

[0153] c) ELISA method for determination of osteocalcin (intracellular and extracellular):

[0154] Osteocalcin secretion by MG-63 cells in response to addition of ionic lysates of each fluorophosphate bioglass sample to the culture (extracellular as well as intracellular) at concentrations of 100 μg, 10 μg and 1 μg was analyzed by ELISA.

[0155] MG-63 cells were seeded into 24-well plates (2×10 5 Cells / well). After overnight adhesion, the culture medium was removed and washed with Dulbecco's PBS. Ionic lysates of various fluorophosphate bioglass samples at various concentrations were added to the wells (culture medium without phenol red, serum, and antibiotics). The assay plate was placed in a CO2 incubator containing 5% CO2 at 37°C for 72 hours. After incubation, the supernatant was used to analyze osteocalcin expression in the extracellular environment.

[0156] In order to evaluate the intracellular expression of osteocalcin, cell digestion enzyme (Accutase) (Gibco) was used to separate and collect cells from the wells. 200 μL cell lysate (Sigma) was added to each well and cultured for 10 minutes. The lysed cell components were centrifuged and the supernatant was taken for intracellular evaluation. 100 μL was taken out from each sample and evaluated by ELISA method. The experiment was carried out according to the instructions provided by the manufacturer (DIA source hOST-EASIA kit, Belgium). The absorbance was read at 450nm. The expression of osteocalcin was calculated by drawing a standard curve, and the numerical value was expressed in ng / mL (Tables 1 and 2).

[0157] Table 1: Extracellular osteocalcin secretion produced by ionic lysates of various metal oxide-doped FP glasses in MG63 cells.

[0158] Table 2 shows the extracellular expression of osteocalcin, expressed in ng / mL

[0159]

[0160] Bone is a composite of a base material reinforced by various collagens and mineralized by hydroxyapatite. Although various collagens are present in various parts of the body, osteocalcin is only present in bones. It is also an excellent genetic marker for osteoinduction. The ability of ionic lysates of various FP glasses at various concentrations to promote the efficiency of osteocalcin secretion was evaluated. Although the extracellular expression of osteocalcin increased compared to the controls using only ZnFP and MgFP (Table 1), intracellular osteocalcin was elevated in most glasses, with significant increases in ZnFP, MgFP, and AgFP glasses, and more increases when the concentration of the lysate was 10 μg / mL (Table 2).

[0161] Based on the above studies and the characteristics of fluorophosphate glass, AgFP, ZnFP, and MgFP are selected to prepare the composite material and process the composite material into a desired structure and shape.

[0162] Embodiment 2:

[0163] a) Selection and characterization of biopolymers

[0164] The properties of bio-inert and bio-active polymers were characterized. PPF and 1,2-diol were synthesized at Department of Polymer Technology, Kamarai Institute of Engineering and Technology, SPGC Nagar, K.Vellakulam-625 701, India. Medical grade PLA and PDLLA were purchased from Japan Structural characterization (FTIR-8400S spectrophotometer, Shimadzu, Japan) and thermal evaluation (TA Instruments DSC Q20) were performed ( Figure 3-8 ).

[0165] b) Evaluation of the effective percentage of FP glass

[0166] The optimal percentage of FP glass ( Fig.10 and 11 ). The strength and ductility of the prepared materials were manually checked. Also, as in previous studies, cell attachment in the composites was evaluated to select the correct percentage of glass powder (10, 12.5, 15, and 17.5%) (Tables 3 and 4).

[0167] Table 3

[0168]

[0169] Table 4

[0170]

[0171] c) Effect of increasing biopolymer composition

[0172] Among the four biopolymers, PLA and PDLLA are bioinert, PPF and 1,2-diol as well as FP glass are bioactive. With the minimum reduction of bioinert PLA, the contribution of bioactive components increases. The PLA share decreases stepwise from 63.69% to 53.89%. It was replaced by increasing FP glass to make 5 scaffolds. They were cultured with MG63 cell line for 21 days as per the previously mentioned protocol and the number of adherent and dead cells were tabulated. (Tables 5 and 6)

[0173] Table 5

[0174]

[0175] Table 6

[0176]

[0177]

[0178] It was observed that the composite with 75% glass was tough and broke when bent. The composite with lower glass content did not break and was elastic ( Fig.10 ,11). When the percentage of PPF / 1,2-diol in the polymer group was very small (3%), the composite did not break, which not only indicated the bioactivity of PPF / 1,2-diol but also its ability to change the physical properties of the composite.

[0179] d) Effect of varying the percentage of PLA and PDLLA with fixed PPF / 1,2-diol and FP glass

[0180] Scaffolds were fabricated by keeping the ratio of the bioactive components PPF / 1,2-diol and FP glass constant and varying the ratio of the bioinert components, increasing the percentage of PLA while decreasing the percentage of PDLLA. Cell adhesion studies as well as the number of live and dead cells were evaluated as previously described and tabulated (Tables 7, 7a and 8, 8a).

[0181] Table 7

[0182]

[0183] Table 7a

[0184]

[0185]

[0186] Table 8

[0187]

[0188] Table 8a

[0189]

[0190] Cell adhesion to the scaffold and the underlying glass plate was improved by 1) changing the ratio of FP glass to prepare the scaffold; 2) increasing the percentage of the bioactive components PPF / 1,2-diol and FP glass while reducing the bioinert components to prepare the scaffold; 3) changing the percentage of the bioinert components PLA and PDLLA while keeping the bioactive components fixed to prepare the scaffold, as shown in Tables 3, 5, 7, and 8.

[0191] The best results were obtained when the bioactive component (PPF / 1,2-diol + FP glass) was in the range of 10-30% and the relatively bioinert component (PLA + PDLLA) was in the range of 54-67% (Tables 4, 6, 7a and 8a).

[0192] e) Changes in the biological effects of components

[0193] To evaluate how the osteoblast-like cell line MG-63 adheres to scaffolds composed of various combinations of polymers, scaffolds of 1) PLA, 2) PLA and PDLLA, 3) PLA, PDLLA and PPF, and 4) PLA, PDLLA, PPF and FP were prepared. Glass scaffolds were cut into 12 mm circles using a cork drill, UV sterilized, washed with PBS and immersed in serum-free MEM for 1 hour. The scaffolds were then transferred to 24-well plates and MG-63 cells (5X 104 ) were seeded onto the scaffold. The plates were cultured in a CO2 incubator with 5% CO2 at 37°C for 1, 7, 14 and 21 days. Minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 50U / mL penicillin, 50mg / mL streptomycin and 1% L-glutamine (Gibco) was used throughout the experiment. To avoid nutrient depletion, the culture medium was replaced every two days for wells cultured for 7, 14 and 21 days. After culture, a phase contrast microscope (Olympus, Japan) with a camera add-on software (Magnus Analytics Mag Vision software; version – x 64, 3.7.6820) was used to observe and record the wells with scaffolds to obtain the maximum number of attached cells. ( Fig.12 ).

[0194] The evaluations conducted in the MG63 cell line focused on the bioactivity of PPF and FP glasses. By adding small amounts of PPF, it was apparent that almost zero or negligible cell adhesion became possible, and by adding FP glasses this possibility was significantly increased. This effect was shown in Figure 2. Fig.12 shown.

[0195] Example 3: Porosity Evaluation

[0196] a) Film integrity (Calcein AM) testing related to porous / non-porous, + / -PPF / XPPF, + / -FP glass

[0197] Twelve different scaffolds were made to evaluate the importance of porosity. Cell membrane integrity and cell morphology were assessed by double staining. 1*10 5 SaOS2 cells were cultured at 37°C and 5% CO2 for 24 h. The cell supernatant was aspirated. The scaffolds were gently washed with ice-cold PBS solution, and finally 2 μM calcein AM was added and cultured at 37°C for 10 min. The cells were observed under a microscope. Fig.13 ).

[0198] Calcein AM studies to assess cell wall integrity and dual staining to assess cytotoxicity showed interesting features. The cells in the control group were not only bright green, but also had a uniform spindle shape, indicating cell wall integrity and metabolic potential. The addition of PPF to the base component PLA+PDLLA increased cell wall integrity, and the addition of pores to it increased the number of spindle-shaped cells.

[0199] Adding FP glass to the base composition PLA+PDLLA, both with and without holes, significantly increased the number of cells, but their quality was poor, showing round rather than spindle shape of healthy cells.

[0200] The fluorescence intensity and cell mass also increased when all components PLA+PDLLA+PPF and FP glass were added, especially when pores were added to the composite.

[0201] When XPPF (self-polymerized PPF) replaced PPF in the composite, only detrimental effects on fluorescence and cell quality were observed ( Fig.13 ).

[0202] b) MTT test related to porous / non-porous glass, + / -PPF / XPPF, + / -FP glass

[0203] The MTT assay was used to assess mitochondrial activity in living cells. Cells were seeded in 12-well plates at 1x10 5 The density of cells / well contained the test material and was cultured at 37°C for 24 hours. After culture, the cell culture medium was aspirated, 10 μL MTT (5 mg / mL) was added to each well, and cultured for 4 hours. Afterwards, the obtained formazan crystals were dissolved in 100 μL / well of DMSO and quantified by measuring the absorbance at 550 nm using a Perkin Elme microplate reader. The data are expressed as a percentage of the control (untreated cells). (Table 9).

[0204] Table 9

[0205]

[0206] From the above studies, it can be inferred that the least toxic composite material is PLA+PDLLA+PPF+FP glass (porous) (Table 9).

[0207] Example 4: Preparation of composite materials and scaffold fabrication

[0208] The porous scaffolds were prepared by four different methods (salt leaching, gas foaming, gel pressing, and precipitation-freeze drying) ( Fig.14 ).

[0209] Salt Dipping:

[0210] Take the calculated amount of PLA, PDLLA, PPF / diol and AgFP / ZnFP / MgFP and mix them with dichloromethane. 12 H 22 O 11 ) was sieved in 300 and 100 μ mesh screens and added on a 30% V / V basis. The porogen was mixed with the mixture using a magnetic stirrer at 300 rpm. The slurry was poured into a Teflon film coated culture dish and placed in a warm room for 24 hours. After drying, the film was compressed at 70°C for 10 minutes. The porogen was leached out using double distilled water by ultrasonic treatment. The prepared scaffold was dried in a laminar air hood.

[0211] Gas foaming

[0212] Calculated amounts of PLA, PDLLA, PPF / diol and AgFP / ZnFP / MgFP were taken and mixed with dichloromethane. The porogen (ammonium bicarbonate - NH4HCO3) was sieved in 300 and 100 μ mesh screens and added on a 30% V / V basis. The porogen was mixed with the mixture using a magnetic stirrer at 300 rpm. The slurry was poured into a Teflon film coated Petri dish and placed in a warm chamber for 24 hours. After drying, the film was immersed in hot water, carbon dioxide emission occurred, and pores were generated. Once all the bubbles settled, the scaffold was placed in ice-cold ethanol for 2 minutes. The fabricated scaffold was dried under a laminar air hood for 24 hours.

[0213] Gel compression

[0214] Take the calculated amount of PLA, PDLLA, PPF / diol and AgFP / ZnFP / MgFP and mix them with dichloromethane. 12 H 22 O 11 ) was sieved in 300 and 100 μ mesh screens and added on a 30% V / V basis. The porogen was mixed with the mixture using a magnetic stirrer at 300 rpm. The slurry was poured into a Teflon film coated culture dish and placed in a warm room for 24 hours. After the solvent was completely evaporated, the two layers of film were pasted with dichloromethane and compressed at 70°C for 10 minutes. The porogen was leached out using double distilled water by ultrasonic treatment. The prepared scaffold was dried in a laminar air hood.

[0215] Precipitation-freeze drying

[0216] Take calculated amounts of PLA, PDLLA, PPF / diol and AgFP / ZnFP / MgFP and mix with dichloromethane. Slowly pour the solution into ice-cold ethanol (non-solvent) under effective stirring. Obtain a fibrillar precipitate and wash with double distilled water. Load the precipitate into a cylindrical tube. Centrifuge the obtained precipitate at 3000 rpm for 15 minutes and store in a refrigerator for 12 hours. Freeze-dry the scaffold for 8 hours.

[0217] Gel foam casting with rapid heating

[0218] Take the required amount of PLA, PDLLA, PPF / diol and AgFP / ZnFP / MgFP and mix with dichloromethane at 300 rpm under a magnetic stirrer. Once the mixture is homogenized, pour the composite slowly onto a hot glass plate (70°C). The solution starts to boil and releases dichloromethane. As the solvent evaporates, random pores are generated. Despite the different densities of the four components, continuous boiling keeps the composite uniform. After complete evaporation, a highly interconnected porous scaffold with uniform distribution of components is obtained. ( Fig.14a , 14b The scaffold thus produced can be made into a marsealised powder, cut into strips or rolled into a cylinder. The same process was repeated with different solvents: acetone, toluene and chloroform, with the same results.

[0219] The basic problem of homogenizing the components is that all three polymers chosen are soluble only in organic solvents, whereas the basic bioactive inorganic component is highly hydrophilic and soluble only in water. Another problem faced by the homogenizing components is their overall differential density. In addition to homogeneity, another prerequisite is the basic need for porosity and interconnected pores for better bioactivity. Conventional methods such as salt leaching, gas leaching, gel pressing, precipitation and freeze drying have failed to achieve the required homogeneity and porosity. The high density FP glass powder settles in the matrix of the composite ( Fig.14 ). Also at the end of all these procedures, the holes designed to be about 200 microns were squeezed to about 10 microns due to compression ( Fig.14a ). However, when the gel foam casting and rapid heating methods are combined, the continuous boiling provides the required uniformity and the evaporation of the solvent provides the required porosity ( Fig.14b ).

[0220] The following composites were prepared and evaluated according to the gel foam casting under rapid heating described above.

[0221] Table 10a

[0222]

[0223]

[0224] Table 10b

[0225]

[0226] Example 5: Cytotoxicity evaluation of the fabricated composite material used as a scaffold:

[0227] MTT test:

[0228] The nontoxic properties of the fabricated scaffolds were evaluated by the Saos-2 cell line (ATCC-85). 5×10 cells were cultured in a control medium supplemented with 10% fetal bovine serum, 200 mM L-glutamine, 10 mM ascorbic acid, β-phosphate, 100 U / mL penicillin, and 100 μg / mL streptomycin. 6 25th generation SaOS2 cells. Culture the cells for 24-48 hours to reach confluence. Wash the confluent SaOS2 cells twice with 1X PBS. 2 The scaffolds were placed in 6-well plates and cultured for 48 h. Cell morphology was observed under an inverted microscope. The scaffolds were carefully removed, MTT was added and cultured for 4 h. The resulting formazan crystals were dissolved with DMS. The OD values ​​were measured at 405 nm using a microplate reader, and the readings were tabulated. (Table 11).

[0229] Table 11

[0230]

[0231] The same procedure was performed on a human endothelial cell line and the results of cell morphology changes were recorded ( Fig.15 and 15a ).

[0232] The cytotoxicity of the composites was evaluated by cytotoxicity assessment of human endothelial cell line and SaOS2 cell line. For HE cell line, except for two composites (PLA+PPF+AgFP and PLA+PPF+ZnFP), the survival rates of all other composites were more than 80% ( Fig.15 , 15a Except for two composite materials (PLA+PDLLA+PPF+ZnFP and PLA+PPF+MgFP), the survival rates of the other 10 cell lines of SaOS2 were all higher than 80% (Table 11).

[0233] Example 6: Biological evaluation of the fabricated composite material used as a scaffold:

[0234] 1) Alkaline phosphatase (ALP) activity of scaffolds

[0235] 1*10 6MG63 cells were seeded in a culture plate and cultured at 37°C in a 5% CO2 incubator for 48 hours. Once the cells were fused, 2cm*2cm of each scaffold sample was treated and cultured in each well. After 48 hours of culture, the cells were washed twice with ice-cold PBS and homogenized in 50μL of assay buffer. The insoluble material was centrifuged at 13,000rpm for 3 minutes. Test samples with different concentrations of exudate were added to a 96-well plate, and then 10μL of ALP was added to each well. Then, 50μL of 5mM pNPP solution was added to each well containing the test sample. The reaction mixture was cultured at 25°C for 60 minutes under dark conditions. 20μL of stop solution was added to terminate the ALP activity in the sample. The OD value was measured at 405nm with a microplate reader, and the results are listed in the table. (Table 12).

[0236] Table 12

[0237] The fabricated composites were evaluated for their ability to enhance the secretion of alkaline phosphatase (ALP) in the SaOS2 cell line. ALP is an important factor involved in most stages of bone tissue formation. The values ​​obtained showed that only the 1,2-diol and AgFP / ZnFP composites showed higher secretion than the control, while the composites containing PPF showed similar secretion to the control. For the composites containing MgFP, all four types showed lower activity than the control (Table 12).

[0238] 2) The secretion of osteocalcin, collagen II, and Run X2 in the composite material as a scaffold was analyzed by RT PCR Conduct an assessment

[0239] This study was performed in the SaOS2 cell line. TRIzol was used according to the manufacturer's protocol. TM Total RNA was isolated from osteoblasts using the NanoDrop spectrophotometer. RNA concentration was determined at 260 / 280 nm. For reverse transcription polymerase chain reaction (RT-PCR), the SuperScript TM cDNA was synthesized using the First Strand Synthesis System (Thermo Scientific). The synthesized cDNA was stored at 20°C for later use. Collagen II ( Fig.16 and 18 )、OCN( Fig.17 and 18 ) and Runx2( Fig.19 ) genes at the same time gene expression levels.

[0240] Temperature and time cycle program

[0241]

[0242] The real-time PCR reaction mixture (50 μL) was prepared as follows: 25 μL SYBR Green Mix (2x), 0.5 μL liver cDNA, 2 μL primer pair mixture (5 pmol / μL for each primer), and 22.5 μL water.

[0243] The primers used for PCR are as follows:

[0244] Type II collagen

[0245] Forward primer: CATGAGGGCGCGGTAGAGA

[0246] Reverse primer: ATCCCCTCTGGGTCCTTGTT

[0247] Product length: 296

[0248] Osteocalcin

[0249] Forward primer: TCACACTCCTCGCCCTATTG

[0250] Reverse primer: CTCTTCACTACCTCGCTGCC

[0251] Product length: 132

[0252] Runx2 sequence (5'->3') Template chain length Start end Tm GC% Self-complementarity Self-3' complementarity Forward primer: CCACCGAGACCAACAGAGTC Plus (+)

[0253] Reverse primer: GTCACTGTGCTGAAGAGGCT

[0254] Product length: 119.

[0255] Using the ABI The results were analyzed using the 7000 Sequence Detection System software, which is able to estimate relative gene expression more sensitively and accurately. The results were tabulated (Table 13).

[0256] Table 13

[0257]

[0258] The three essential gene markers in bone synthesis from the mesenchymal stem cell stage to the osteocyte maturity stage are osteocalcin, collagen II, and RUN-X2. When the results were plotted to examine the fold change compared to the control, the PLA+PDLLA+PPF+AgFP had the highest fold increase in collagen II, while the osteocalcin fold increase was also the highest when AgFP was included but with 1,2-diol instead of PPF. The highest fold change in RUN_X2 compared to the control was when ZnFP was combined with PLA+PDLLA+PPF. All Mg-based composites performed poorly for all three types of gene markers. (Table 13, Figure 16-19 )

[0259] c) Chondroitin sulfate test of scaffolds:

[0260] SaOS2 cell line was cultured with various composite materials for 48 hours. Cells were washed 3 times in cold PBS and resuspended in PBS (1x), frozen at ≤-20°C and thawed. The freeze / thaw cycle was repeated 3 times. Cell debris was removed by centrifugation at 1,500xg for 10 minutes at 2-8°C. Chondroitin sulfate was measured using a competitive ELISA method (Robonik, India). Fig. 20 (Table 14).

[0261] Table 14

[0262] The results showed that all twelve composites showed many-fold increases in CS secretion compared to the control, regardless of whether the component contained 1,2-diol or PPF, and whether the FPglass was Ag, Zn, or Mg (Table 14).

[0263] Example 7: In vitro evaluation of scaffolds:

[0264] 1) Prepare simulated body fluid (SBF) according to the standard Kokubo protocol. Cut all the prepared scaffolds into 2*2cm 2 Size. The scaffolds were placed in a glass container filled with 20 mL SBF and placed in a 5% CO2 incubator (Heraus - Germany) for 21 days. The pH changes were recorded every day using a pH meter E1 model. After 21 days, the scaffolds were carefully removed; dried in a laminar air flow for 48 hours. The changes in pH values ​​of all samples over 21 days were plotted in a graph. (Table 15)

[0265] Table 15

[0266]

[0267] The pH changes of all compression molded samples showed a decrease in the first 2 days, which was caused by the formation of phosphoric acid. +and / or Ca 2+ ) release, all samples rebounded to 7 on the third day. Therefore, the dissolution of ions makes the cations (Na + and / or Ca 2+ ) instead of H + ions, resulting in an increase in the hydroxide ion concentration. Even in the first two days, none of the samples fell below 6.5. Afterwards, it showed a stable change between 7 and 6.7.

[0268] The scaffolds, single-layer strip scaffolds and multi-layer cylindrical scaffolds made by gel foam casting under rapid heating even showed better pH values ​​in the first two days, and never fell below 6.8, and the pH value in the final stage was also higher than that of the compression-molded scaffolds. The highest pH reached by the scaffold band made by the rapid heating method was 7.15. This change shows better uniformity and porosity obtained by the rapid heating method, avoiding the highly acidic environment that may cause failure (Table 15).

[0269] 2) XRD

[0270] XRD evaluation was performed on the samples before and after immersion (before and after immersion refers to before the stent was immersed in SBF and after immersion in SBF and drying). X-ray diffraction patterns were obtained using a PANalytical X'PertPRO powder X-ray diffractometer. The Scherrer equation was used to semi-quantitatively calculate the crystal size of the deposited material.

[0271] D=kλ / βcosθ

[0272] in:

[0273] D is the average size of the ordered (crystalline) domains, which may be less than or equal to the grain size, which may be less than or equal to the particle size; (nm)

[0274] k is a dimensionless shape factor with a value close to unity. Typical values ​​for the shape factor are about 0.9, but vary with the actual shape of the crystallite;

[0275] λ is the wavelength of X-rays; λ = 0.15406 nm

[0276] β is the line broadening at half the maximum intensity (FWHM) in radians after subtraction of the instrumental line broadening.

[0277] θ is the Bragg angle. (Table 16)

[0278] Table 16

[0279]

[0280]

[0281] XRD of three samples prepared by combining rapid heating and gel foam casting was evaluated before and after immersion (Table 17).

[0282] Table 17

[0283]

[0284] In the XRD evaluation, the crystal size (D) of the deposited material was calculated by the Schrrer equation for the state before and after immersion. Among the values ​​before immersion, the crystal size of PLA+PDLLA+PPF+AgFP showed the highest value. This is attributed to the high hydrophilicity of the composite material and its reaction with atmospheric humidity during the waiting and evaluation period of the support (Table 16). The same effect was observed in the support made by gel foam casting under the rapid heating method, and the maximum size of the crystal was observed with the same AgFP composite material (Table 17).

[0285] 3) FITR analysis:

[0286] A small amount of the sample before and after immersion (before and after immersion refers to the stent before immersion in SBF and after immersion in SBF and drying) was ground with potassium bromide and made into pellets. The pellets were used for analysis. The Fourier transform infrared-8400S spectrophotometer of Shimadzu Corporation was used at 500-4000cm -1 The analysis was performed within the spectral range. Figure 21-26 ).

[0287] The main functional groups of the composites seen in the respective spectral ranges in the FTIR evaluation are alcohols (3200-3500 cm -1 ), alkanes (2850-3000cm -1 ), saturated ketone (1735-1750cm -1 ), olefins (1630-1680cm -1 ), asymmetric methyl bend (1450-1470cm -1 ), methyl bend (1350-1395cm -1 PO bending (560-500cm -1 ) bands indicate the formation of calcium phosphate (CaO-P2O5) layers. Carbonate groups (CO3) 2- (1400-1550cm -1 ) band shows the crystalline nature of the HA layer. -1 The bands observed above correspond to OH groups. After 21 days of immersion in SBF, (CO3) 2- The strong intensity and frequency shift of POP stretching and PO bending groups reveal the interaction between the composite and HAp precipitation. Figure 21-26 ,21a-26a).

[0288] 1450-1410cm -1 The acromion plus 870-875cm -1 The weaker peak at 1450-1410 cm corresponds to the vibration of B-type carbonate, while the vibration region of A-type carbonate is 1450-1410 cm -1 Plus 880cm -1 A- and B-type carbonates are not distinguishable in these scaffolds because the ester peaks are also located in the same region. Both A- and B-type carbonates are present in these scaffolds and their intensity is the highest in the three selected compression molded scaffold composites (PLA+PDLLA+PPF+ZnFP, PLA+PDLLA+PPF+AgFP, PLA+PDLLA+PPF+MgFP). For the same composites, the corresponding peak of HAp in the case of rapid heating combined gel foam casting is higher than that of compression molded scaffolds.

[0289] Although HAp precipitation was observed in all fabricated scaffolds, in the case of gel foam casting under rapid heating, the carbonation groups (CO3) 2- and phosphate groups (asymmetric and symmetric stretching of POP, bending of PO) are significantly higher than those of the corresponding composites made by compression molding. Figures 21a-26a )

[0290] 4) SEM_EDAX

[0291] The morphological analysis and semi-quantitative element concentration of the samples prepared by compression molding and pores made by sugar infiltration were examined before and after immersion using a scanning electron microscope-SEM (Ultra 55; Zeiss, Oberkochen, Germany) coupled with an energy dispersive X-ray spectrometer (Model Oxford Xmax50 EDS, Oxford Instruments, UK) after gold sputtering. Fig.28 )

[0292] The sample was cut in half to expose the interior of the scaffold. The exposed interior surface was sputtered with gold and analyzed using the same scanning electron microscope. Fig.28a )

[0293] The crystal width relative to the actual width of the sample was calculated as a percentage and tabulated to evaluate the scaffolds for biotransformation (Table 18).

[0294] Table 18

[0295] Sample code %Crystallinity PLA+PPF+ZnFP 87.31 PLA+PDLLA+PPF+ZnFP 76.19 PLA+PPF+AgFP 49.36 PLA+PDLLA+PPF+AgFP 72.7 PLA+diol+ZnFP 59.54 PLA+PDLLA+diol+ZnFP 78.89 PLA+diol+AgFP 86.88 PLA+PDLLA+diol+AgFP 97.42 PLA+PPF+MgFP 94.62 PLA+PDLLA+PPF+MgFP 82.09 PLA+diol+MgFP 73.33 PLA+PDLLA+diol+MgFP 78.68 PLA+PDLLA+PPF+ZnFP(RH) 73.62 PLA+PDLLA+PPF+AgFP(RH) 81.42 PLA+PDLLA+PPF+MgFP(RH) 87.34

[0296] The single layer of the composite material was cast by gel foam under rapid heating. Cylinders with a core diameter of 5 mm were made from the composite material. After sputtering of gold, the single layer samples and multilayer cylinders prepared by rapid heating gel foaming were subjected to SEM evaluation. (Ultra 55 model; Zeiss, Oberkochen, Germany) Fig.30 )

[0297] Similar specimens were evaluated in vitro and analyzed in the same manner in the same scanning electron microscope to assess the extent of surface porosity and changes in crystallinity after the in vitro studies ( Fig.30a Clinical photographs of ribbon composites and cylindrical composites, both made by coacervate foam casting under rapid heating, show that the shape remains unchanged after 21 days of SBF immersion, but the color and texture have completely changed, indicating crystal transformation ( Fig. 27 ). Fig.28 SEM of compression molded scaffolds at two different magnifications before and after in vitro evaluation are shown, showing very little crystallization and well-displayed uniform pores before in vitro evaluation. After 21 days of immersion in SBF, crystal transformation can be clearly seen and all pores are almost completely blocked by the formed crystals.

[0298] The samples after SEM study were divided into two halves and the thickness crystallinity percentage of the inner part was evaluated by SEM ( Fig.28a ). The percentages did not change significantly, and it can be inferred that once the pores allow SBF to penetrate into the interior, the conversion rates of all composites are close to equal, except for a certain effect on the degree of crystal conversion when PDLLA is absent (Table 18).

[0299] In vitro state SEM studies of ribbon-like scaffolds made by gel foam casting under rapid heating previously showed crystal spots, indicating the high hydrophilicity of the scaffolds ( Fig.31 ), post-immersion evaluation of the same sample showed complete conversion to crystallinity, demonstrating the high bioresorbability of the scaffold ( Fig.31 ).

[0300] Low magnification SEM evaluation of the cylindrical scaffolds produced by rapid heating showed ample pores. This demonstrates that the polymer can be homogenized by the simple method used ( Fig.30 ). SEM before and after in vitro clearly showed that complete crystallization had occurred ( Fig.30a EDX evaluation of SEM before and after in vitro confirmed the high level of carbonated hydroxyapatite formation in the scaffolds ( Fig.30b ).

[0301] 5) Micro-CT evaluation

[0302] The surface and internal structure of single-layer ribbon-shaped stents and multilayer cylindrical stents were evaluated at various voxels using a GE SRμCT analyzer and 3D reconstruction was performed. Porosity was evaluated in all three planes (axial, coronal, and sagittal). This revealed the degree of porosity and interpore connectivity. Fig.29 ).

[0303] The samples were evaluated in vitro (immersion in SBF at 37°C, 5% CO2 for 21 days) and the changes were documented by photographs ( Fig. 27 ). Micro-CT evaluation after immersion showed complete crystallization. ( Fig.29a )

[0304] MICRO-CT evaluation of cylindrical scaffolds made by rapid heating gel foam casting demonstrated the following factors: a) the scaffolds were not delaminated and were continuous; b) there was sufficient porosity and the pore sizes were varied; c) the pores were well connected through interpores ( Fig.29 After in vitro evaluation, the same sample had the property of fully transforming into a crystalline state and retaining the deeper pores ( Fig.29a ).

[0305] Example 8: In vivo evaluation of composite particles

[0306] The in vivo studies were performed under ethics committee approval (ethics committee approval number ABS / IAEC / 18-10-2019 / 003-).

[0307] Single species of rabbits (Orictologus cuniculus) were purchased from King Institute, Chennai, India, and acclimated within two weeks. The circadian rhythm was maintained and a nutritious diet was fed. The body weight gain of 150 g (1800-1950 g) within two weeks confirmed the adaptability. The scaffolds were crushed to prepare composite (PLA+PDLLA+PPF+AGFP) particles and sterilized with ethylene oxide gas.

[0308] Animals were pre-treated with dichloroacetyl syrup (2.5 ml) 30 minutes before surgery. Ketamine anesthesia was given intramuscularly at a dose of 45 mg per kg of body weight, and 10 minutes were allowed for complete dissociative anesthesia. Anesthesia was maintained by inhalation of oxygen and sevoprim via mask.

[0309] The left thigh was repeatedly painted with 10% povidone-iodine and ethanol. 2% lidocaine was injected with epinephrine into the incision line as an additional analgesic and hemostatic agent. The anterolateral skin incision was rolled down to expose the posterior edge of the quadriceps femoris. Using sharp dissection, the muscle was incised and enlarged through a fine bone spur to expose the anterolateral side of the femur. A 2 cm long groove was made using a 1 mm electric dental drill. The medullary cavity was exposed. It was filled with sterile composite powder. Washed with open saline to wash away the overflowed composite. Once the spurs were removed, the muscle fell back into a position that completely covered the bone groove. Two 3-0 vicryl stitches were used to suture the muscle. The skin incision away from the working bone was closed with 3-0 ethilon. A single dose of ceftriaxone 250 mg ( Fig.32 ). The femur was found to be fractured and separated at both ends ( Fig.34 ). No fixation or any form of immobilization of the femur was performed. The rabbit was not lame and was eating well. On postoperative day 9, only glints were present at the fracture ends without any evidence of callus. One week later (day 16), the limb was well united on clinical examination. X-rays taken showed a large amount of callus not only at the fracture ends, but also along the femur forming the groove and even below ( Fig.33 ).

[0310] The animals were euthanized, the limbs were removed, the skin and muscles were peeled off, and a large amount of callus was found to be very firmly integrated with the fracture. The dissected specimens were X-rayed and preserved in 10% formalin. Fig.34 )

[0311] The samples were prepared and decalcified samples were sectioned axially to reveal two segments of the femur with formed intervening tissue. The samples were stained using conventional eosin-hematoxylin and von Kossa stains. (Figure 36).

[0312] The procedure used is shown successively in the photographs ( Fig.32 Although the limb was broken, no special treatment was given. On the 9th day, it was still difficult to recover, but on the 16th day, it had fully grown ( Fig.33 ). X-rays of the autopsy specimen showed that the callus extended almost throughout the femur ( Fig.34 HPE is particularly interested in the tissue between the fracture ends filled with particles ( Fig.35). The important observations were a) almost all particles were absorbed except for occasional traces; b) abundant cartilage formed between the ends, indicating endochondral ossification; c) woven bone formed between the fracture ends demonstrated how quickly fusion occurred; d) the absence of multinucleated giant cells indicated the biocompatibility of the composite; e) similar features were observed in both stainings (Figure 36). The improved tetrachrome staining provided more information than the above two stainings. It can be clearly seen that a) new lamellar bone is continuously formed as the composite particles are absorbed; b) the sound fusion of woven bone formed by endochondral ossification; c) the abundance of osteoblasts and osteoid; d) the vigorous neovascularization in fibroblasts (Figure 37-abcd).

[0313] Example 9: In vivo evaluation of composite strips

[0314] The in vivo studies were performed under ethics committee approval (ethics committee approval number ABS / IAEC / 18-10-2019 / 003-).

[0315] Three male rabbits were purchased and tamed in the same way as explained above. AgFP / ZnFP / MgFP composites were prepared with PLA+PDLLA+PPF under rapid heating using gel foam casting. They were 1 mm thick and cut into 2*20 mm sizes. The cut samples were sterilized by ethylene oxide gas sterilization.

[0316] The animals were anesthetized, the limbs were prepared and the femurs were exposed as described in previous studies. A narrow incision was made with a 701 taper bur at a 45° angle to the femur, making it very thin. A 3-0 Velcro was threaded around the femur, leaving both ends free. Two layers of 2×20 mm sterile composite were left over the incision to allow the bone marrow blood to plug the sample. Velcro was tied around the sample so that it would not slip or move away and the wound would close in layers ( Fig.38 ). This procedure was performed on all three samples from each animal.

[0317] The animals were maintained on a nutritious diet during the postoperative period. Radiographs on the first day did not show the specimen in either view because the specimen was translucent to the radiograph. Radiographic evaluations were performed under sedation on days 1, 9, and 16 ( Fig.39a , 39b , 39c). Clinical healing occurred as early as day 15. CT evaluation was performed on day 19. (Figs. 40, 40a, 40b) Animals were euthanized according to the protocol, and limbs were harvested, skin and muscle stripped, and bones preserved in 10% formalin ( Fig.41 ). The specimens were X-rayed (Fig. 42, 42a) and then histopathologically evaluated under EH staining and eosin staining (Fig. 43, a, b, c, d.).

[0318] Fig.38 The series of photographs in show the procedure used, in which two layers of 1-mm-thick strips are placed over a very narrow corticotomy wound in the femoral shaft and held in place by a single 3-0 vicarioclonal knot. Fig.39a a, b, c show no evidence of composite sheet placement or corticotomy, as the composite is not radiopaque and the groove is narrow. However, radiographs taken on day 9 showed femoral fractures in all three animals. No specific fixation or intervention was performed on the fractures. Clinical healing occurred as early as day 15 and was confirmed by radiographs on day 16 and CT scans on day 19 ( Fig.40a , b, c). Limbs harvested after animal euthanasia show composite strips adhered to underlying bone ( Fig.41 ). The sample radiograph showed a large amount of callus along the fracture (Figure 42), and no composite bands were visible in the radiograph.

[0319] Histopathological evaluation showed the following features ( Fig.43a ): a) The two layers of the scaffold have merged into one layer; b) The composite material has attached to the underlying bone; c) There is abundant woven bone formation below the composite strip at the level of the cortical cut ( Figure 43b d) The second composite strip away from the cortical incision has a large amount of fibroblast infiltration; ( Fig.43c , d); e) Fiber transformation of the composite surface layer with abundant new blood vessel formation. These changes confirm the osteoinductive potential of the composite, the ability of the composite to undergo biotransformation and the high bioactivity of the composite.

[0320] Modified tetrachrome staining of samples with horizontal cross-sections of the composites confirmed the findings of the EH staining and revealed additional features. Fig.44a The transformation of the fragmented composite to form woven bone is shown, so that the cortical incision made is healed, and the combination of the two layers of the composite strip and the layer close to the bone is randomly infiltrated by fibroblasts and osteoid plaques. At higher magnification (44b), the fusion of the composite strip to the underlying bone through the osteoid can be clearly seen. At further magnification (44c), the composite is well penetrated by the newly formed osteoid layer, replacing the dissolved areas of the composite. Fig.44d The adhesion of the composite strips is shown, the composite strips dissolve and break down to form new woven bone, the corticotomy heals, and new osteoid appears in the dissolved portion of the composite.

[0321] Example 10: Preparation of scaffolds by 3D printing

[0322] Fused filament fabrication (FFF) 3D printers are typically used to fuse plastic, extrude it at a higher temperature and cool it to room temperature to build a 3D model into a product.

[0323] A custom 3D printer was built to prepare the composites. The inkjet printer is kept at a relatively low temperature in the printer so as not to lose the homogeneity achieved between the composite components. Fig.45b ). For this purpose, a special cooling chamber is designed. It cools the slurry extruder to 15-20°C. The slurry is extruded onto a plate heated to 100°C and maintained at a chamber temperature of 30-40°C ( Fig.45a The extrusion is controlled by conventional CAD software and the desired design is printed ( Fig.45c ).

[0324] advantage:

[0325] The composite material can be made into granules or powders or a mixture thereof, and can be used as a filler for bone voids caused by injury, infection, bone tumors, which will be converted into bone in a shorter period of time, avoiding amputation and reducing morbidity by reducing the time required for bioconversion.

[0326] Composite materials fabricated into strips can be used as the sole graft, similar to a phenitoplasty graft, the most common type of autologous graft used by plastic surgeons. This would reduce surgical morbidity and avoid a second incision to harvest the autologous graft.

[0327] The composite material as a cylindrical graft can be used as an interposition graft and can preserve many long bones with critical size defects caused by trauma or other injuries.

[0328] The composite material can be customized into a graft through rapid prototyping methods to replace specific parts of the bone when diseased, rather than amputating the limb.

[0329] The synthetic composite material of the present invention has the following characteristics:

[0330] a) Biocompatibility; b) Bioactivity; c) Biodegradability; d) Non-toxic to the recipient; e) Bioconductivity; f) Bioinducibility; g) Bioconvertibility; h) Degradation rate matching the bioconversion rate; i) Sterilizability; j) Ease of mass production; k) Processability into desired shapes; l) Cost effectiveness.

Claims

1. A synthetic composite material for bone graft, comprising: Bioinert polymers including polylactic acid and poly-D,L-lactic acid; A bioactive polymer, which is composed of polypropylene fumarate or a diester of fumaric acid and propylene glycol; and a bioactive inorganic component, which is composed of fluorophosphate metal salt glass powder, wherein the amount of the bioactive inorganic fluorophosphate metal salt glass powder is 10% (w / w) to 30% (w / w) of the composite material.

2. The composite material according to claim 1, characterized in that The metal fluorophosphate glass is selected from zinc fluorophosphate, magnesium fluorophosphate or silver fluorophosphate.

3. The composite material according to claim 1, characterized in that The polylactic acid is 54% (w / w) to 68% (w / w).

4. The composite material according to claim 1, characterized in that The diester of fumaric acid and propylene glycol is 3% (w / w) to 10% (w / w).

5. The composite material according to claim 1, characterized in that The poly D,L-lactic acid is 10% (w / w) to 28% (w / w).

6. The composite material according to claim 1, characterized in that The polypropylene fumarate is 3% (w / w) to 10% (w / w).

7. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, diester of fumaric acid and propylene glycol and zinc fluorophosphate.

8. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, poly D, L-lactic acid, diester of fumaric acid and propylene glycol and zinc fluorophosphate.

9. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, polypropylene fumarate and zinc fluorophosphate.

10. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, poly D, L-lactic acid, polypropylene fumarate and zinc fluorophosphate.

11. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, a diester of fumaric acid and propylene glycol, and magnesium fluorophosphate.

12. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, poly D, L-lactic acid, diester of fumaric acid and propylene glycol and magnesium fluorophosphate.

13. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, polypropylene fumarate and magnesium fluorophosphate.

14. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, poly D, L-lactic acid, polypropylene fumarate and magnesium fluorophosphate.

15. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, a diester of fumaric acid and propylene glycol, and silver fluorophosphate.

16. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, poly D, L-lactic acid, diester of fumaric acid and propylene glycol and silver fluorophosphate.

17. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, polypropylene fumarate and silver fluorophosphate.

18. The composite material according to claim 1, characterized in that The composite material comprises polylactic acid, poly D, L-lactic acid, polypropylene fumarate and silver fluorophosphate.

19. The composite material according to claim 1, characterized in that The composite material is one of a powder and a scaffold.

20. A method for preparing the synthetic composite material according to claim 19, the method comprising the following steps: Mixing the synthetic composite material according to claim 1 in a solvent with a magnetic stirrer or ultrasonic treatment to obtain a uniform mixture; The mixture is poured onto a hot glass plate and the solution is brought to a boil; Evaporation of the solvent by continuous boiling; and The result is an interconnected porous scaffold with uniform distribution of the composite material components.

21. The method of claim 20, wherein: The solvent is one of dichloromethane, acetone, toluene or chloroform.

22. The method of claim 20, wherein: The porosity of the porous scaffold is 20%-40%.